Alzheimer's Disease: Targets for New Clinical Diagnostic and Therapeutic Strategies, 1st Edition (e-Book) book cover

Alzheimer's Disease

Targets for New Clinical Diagnostic and Therapeutic Strategies, 1st Edition

Edited by Renee D. Wegrzyn, Alan S. Rudolph

CRC Press

298 pages

Purchasing Options:$ = USD
Hardback: 9781439827086
pub: 2012-04-26
SAVE ~$36.00
eBook (VitalSource) : 9780429165757
pub: 2012-04-26
from $28.98

FREE Standard Shipping!


In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer's disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. Alzheimer's Disease: Targets for New Clinical, Diagnostic, and Therapeutic Strategies provides a detailed synopsis of the c

Table of Contents

The Amyloid Protein and Alzheimer's Disease. Emerging Principles and Biomarkers in In Vitro Diagnostics for Alzheimer's Disease. Imaging Biomarkers for Diagnosis, Prognosis, and Treatment of Alzheimer's Disease. The Current Status of Alzheimer's Disease Treatment: Why We Need Better Therapies and How We Will Develop Them. New Small Molecule Drug Discovery for Alzheimer's Disease. Alzheimer's Disease: Clinical Aspects. Pathogenic Protein Strains as Diagnostic and Therapeutic Targets in Alzheimer's Disease. Traumatic Brain Injury in the Development of Alzheimer's Disease: Risk Factors, Diagnosis, and Treatment Strategies.

About the Editors

Renee D. Wegrzyn obtained her PhD in applied biology from the Georgia Institute of Technology where she studied the propagation of prion proteins in model systems. Dr. Wegrzyn was awarded an Alexander von Humboldt Research Fellowship for her postdoctoral studies to investigate de novo protein folding at the ribosome. She applied her expertise in protein folding to the challenge of developing in vitro diagnostics for neurodegenerative diseases-including Alzheimer's and prion diseases-as a group leader at Adlyfe, Inc. She is currently a scientific and technical consultant for the Department of Defense.

Alan S. Rudolph is currently a member of the senior executive service and director of Biological and Chemical Technologies for the Defense Threat Reduction Agency. He was previously chief executive officer at Adlyfe Inc., an amyloid diagnostic and biomarker company, chief of Biological Sciences at the Defense Advanced Research Projects Agency, and director of Research at the Naval Research Laboratory. He has over 90 publications in diverse areas in biophysics of cryobiology and anhydrobiosis, lipid and protein self-assembly, liposome science and technology, and tissue and cellular engineering. He has a PhD in zoology from the University of California at Davis and an MBA from the George Washington University.

Subject Categories

BISAC Subject Codes/Headings:
MEDICAL / Geriatrics
MEDICAL / Neurology
SCIENCE / Life Sciences / General